Shire plc announced that it has completed its acquisition of Dyax Corp. in an all-cash transaction valued at approximately $5.9 billion, comprised of $37.30 in cash per Dyax share.
Dyax shareholders may receive additional value through a non-tradable contingent value right (CVR) that will pay $4.00 in cash per Dyax share upon approval of DX-2930 for HAE,representing a potential additional $646 million in aggregate contingent consideration.
Shire’s Chief Executive Officer, Flemming Ornskov, MD, MPH, commented:“ The addition of Kalbitor and DX-2930 to our portfolio strengthens our leadership position in HAE and, along with the commercial and research and development expertise at Dyax, is a clear strategic fit for us that advances our position as the global leader in rare diseases.
